Who are Combination of prednisone and azathioprine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ciclosporin and Mycophenolate-mofetil, infliximab+azathioprine, XR-tacrolimus QD + MMF BID then MMF QD, Systemic corticosteroids/methotrexate, Tacrolimus/MMF, XR-tacrolimus QD + MMF BID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combination-of-prednisone-and-azathioprine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Combination of prednisone and azathioprine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of prednisone and azathioprine (Combination of prednisone and azathioprine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant combination. Area: Immunology.

phase 3 Immunosuppressant combination Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Combination of prednisone and azathioprine (Combination of prednisone and azathioprine) — St. Anne's University Hospital Brno, Czech Republic. This combination suppresses the immune system by reducing corticosteroid-mediated inflammation and blocking T-cell proliferation through azathioprine's purine antagonism.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Combination of prednisone and azathioprine TARGET	Combination of prednisone and azathioprine	St. Anne's University Hospital Brno, Czech Republic	phase 3	Immunosuppressant combination
Ciclosporin and Mycophenolate-mofetil	Ciclosporin and Mycophenolate-mofetil	University of Giessen	marketed	Immunosuppressant combination	Calcineurin (ciclosporin); IMPDH type II (mycophenolate mofetil)
infliximab+azathioprine	infliximab+azathioprine	Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW	marketed	TNF-α inhibitor + immunosuppressant combination	TNF-α receptor (infliximab); purine metabolism (azathioprine)
XR-tacrolimus QD + MMF BID then MMF QD	XR-tacrolimus QD + MMF BID then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil)
Systemic corticosteroids/methotrexate	Systemic corticosteroids/methotrexate	Merck KGaA, Darmstadt, Germany	marketed	Immunosuppressant combination (corticosteroid + DMARD)	Glucocorticoid receptor (corticosteroids); dihydrofolate reductase (methotrexate)
Tacrolimus/MMF	Tacrolimus/MMF	University of Miami	marketed	Immunosuppressant combination	Calcineurin (tacrolimus); IMPDH type II (MMF)
XR-tacrolimus QD + MMF BID	XR-tacrolimus QD + MMF BID	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant combination class)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
St. Anne's University Hospital Brno, Czech Republic · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class
University of Giessen · 1 drug in this class
University of Miami · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Combination of prednisone and azathioprine — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-of-prednisone-and-azathioprine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab